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Abstract
Objectives: Closed-loop (CL) systems modulate insulin delivery based on glucose levels measured by a con-
tinuous glucose monitor (CGM). Accuracy of the CGM affects CL performance and safety. We evaluated the
accuracy of the Freestyle Navigator II CGM (Abbott Diabetes Care, Alameda, CA) during three unsupervised,
randomized, open-label, crossover home CL studies.
Materials and Methods: Paired CGM and capillary glucose values (10,597 pairs) were collected from 57
participants with type 1 diabetes (41 adults [mean – SD age, 39 – 12 years; mean – SD hemoglobin A1c,
7.9 – 0.8%] recruited at five centers and 16 adolescents [mean – SD age, 15.6 – 3.6 years; mean – SD hemo-
globin A1c, 8.1 – 0.8%] recruited at two centers). Numerical accuracy was assessed by absolute relative
difference (ARD) and International Organization for Standardization (ISO) 15197:2013 15/15% limits, and
clinical accuracy was assessed by Clarke error grid analysis.
Results: Total duration of sensor use was 2,002 days (48,052 h). Overall sensor accuracy for the capillary
glucose range (1.1–27.8 mmol/L) showed mean – SD and median (interquartile range) ARD of 14.2 – 15.5% and
10.0% (4.5%, 18.4%), respectively. Lowest mean ARD was observed in the hyperglycemic range (9.8 – 8.8%).
Over 95% of pairs were in combined Clarke error grid Zones A and B (A, 80.1%, B, 16.2%). Overall, 70.0% of
the sensor readings satisfied ISO criteria. Mean ARD was consistent (12.3%; 95% of the values fall within
–3.7%) and not different between participants (P = 0.06) within the euglycemic and hyperglycemic range, when
CL is actively modulating insulin delivery.
Conclusions: Consistent accuracy of the CGM within the euglycemic–hyperglycemic range using the Freestyle
Navigator II was observed and supports its use in home CL studies. Our results may contribute toward
establishing normative CGM performance criteria for unsupervised home use of CL.
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Intensive insulin therapy is advocated to reduce therisk of complications in type 1 diabetes, but hypoglycemia
remains a significant barrier to tightening glycemic control.1
There is currently an unmet need to reduce the burden of
diabetes care on patients and healthcare providers. Closed-
loop (CL) systems, which use a control algorithm to direct
insulin delivery autonomously in a glucose-responsive man-
ner by coupling a real-time subcutaneous continuous glucose
monitor (CGM) and subcutaneous insulin delivery by a pump,
may transform the management of type 1 diabetes.2 Over the
past decade, CL research has made incremental progress from
studies performed in clinical research facility and transitional
settings to the home environment.3–5 Unsupervised home
studies provide the ultimate test bed for CL systems and re-
flect daily life conditions without intervention or monitoring
by researchers. As modulation of insulin delivery is based on
CGM sensor glucose levels, sensor performance is important
in determining the efficacy and safety of CL systems.
Accuracy of commercially available CGM devices has
improved over the years. Glucose sensor accuracy studies in
ambulatory patients at home have reported mean absolute
relative difference (MARD), a statistical measure of the
difference between two related measures, of around 12–
19%.6,7 At least 80% of measurements from current CGM
devices lie within Zone A and B, deemed clinically accurate
or benign errors, of the Clarke error grid (CEG) analysis.8
However, glucose sensor accuracy in the hypoglycemic range
as assessed by MARD is known to be worse compared
with during euglycemia.9 There are few published reports of
CGM performance during CL studies. Unsupervised cross-
over home studies provide a unique opportunity to assess
accuracy of real-time CGM across all glycemic ranges during
standard therapy and CL insulin delivery in an environment
reflecting the user’s free-living home conditions.
The present study assessed the accuracy of the Freestyle
Navigator II real-time CGM (Abbott Diabetes Care, Ala-
meda, CA) during two overnight10,11 and one day-and-night12
unsupervised CL home studies under free-living conditions.
Research Design and Methods
Participants
Forty-one adults (18 females, 23 males) and 16 adolescents
(six females, 10 males) with type 1 diabetes were recruited as
part of CL home studies in these two cohorts. All participants
were on insulin pump therapy for at least 3 months prior
to joining these studies. Adult participants were identified
from eligible patients attending Addenbrooke’s Hospital
(Cambridge, United Kingdom), Sheffield Teaching Hospitals
(Sheffield, United Kingdom), King’s College Hospital
(London, United Kingdom), Medical University of Graz (Graz,
Austria), and Profil Institute (Neuss, Germany). Adolescent
participants were enrolled through the Paediatric Diabetes
Clinics at Addenbrooke’s Hospital and University College
London Hospital.
Study design and procedures
Details of the CL study design and experimental protocols
have been described previously.10–12 In summary, following
a 2–4-week run-in phase, participants used insulin pump
therapy with real-time continuous glucose monitoring at
home for two periods with or without CL. Each study period
lasted 4 (adults) or 3 (adolescents) weeks in the overnight
CL studies and 1 week in the day-and-night CL study.10–12
Identical study insulin pump and real-time CGMs were used
during the two study periods, which were separated by a 3–4-
week washout period, during which participants used their
own pump and discontinued continuous glucose monitoring.
Participants were not restricted in dietary intake or daily
activities during either CL or control periods. No supervision
or telemonitoring was provided throughout the study. A 24-h
telephone support service was available for any clinical or
technical issues that arose during the study. User manuals and
troubleshooting literature for the CGM were provided to all
participants.
All participants/guardians provided written informed
consent and assent, as appropriate. The study protocol was
approved by the respective research ethics and regulatory
committees in the United Kingdom, Germany, and Austria.
Continuous glucose monitoring system
The Freestyle Navigator II real-time CGM system13 was
used in all three CL home studies. Participants were instructed
on the insertion and use of the continuous glucose monitoring
system following enrollment into the study. During the CL
and control periods, participants were instructed to calibrate
the sensor according to the manufacturer’s instructions using
the built-in Freestyle glucose meter. In addition, during the
CL period participants were advised to recalibrate the sensor
before going to bed (overnight and day-and-night CL use) or
in the morning (day-and-night CL use) if the sensor was over-
reading by more than 3.0 mmol/L. This advice mitigated the
risk of sensor error leading to insulin overdelivery during CL
operation as assessed by in silico testing14 using the validated
Cambridge simulator.15 Participants were advised to wash
their hands before calibration to reduce measurement errors.
Each Freestyle glucose meter was checked using calibration
fluid prior to the start of the study.
Numerical and clinical accuracy
CGM sensor accuracy was evaluated using data col-
lected during the open-loop and CL periods but not during
run-in or washout periods. Numerical accuracy was assessed
by absolute deviation, absolute relative difference (ARD),
and using the International Organization for Standardization
(ISO) 15197:2013 15/15% limits for acceptability of capil-
lary home glucose monitoring meters16 (95% of the measured
glucose values should fall within either –0.83 mmol/L
[15 mg/dL] of the average measured values of the reference
measurement procedure at a glucose level of <5.55 mmol/L
or within 15% at a glucose level of >5.55 mmol/L). Main
measured outcomes included overall MARD and median
ARD, as well as MARD and median ARD in the euglycemic
(3.9–10.0 mmol/L), hypoglycemic (<3.9 mmol/L), and hy-
perglycemic (>10.0 mmol/L) ranges stratified according to
capillary glucose measurements. A Bland–Altman analysis
plot was used to compare the limits of agreement between
real-time continuous glucose sensor and capillary glucose
values. The percentage of data points of the CEG was used to
evaluate clinical accuracy.
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Statistical analyses
Statistical analyses were performed using SPSS version
21 software (IBM Software, Portsmouth, United Kingdom).
Data are presented as mean (SD) or median (interquartile
range) values unless stated otherwise. Demographics and
clinical characteristic variables in the first and fourth quartiles
were compared using the independent-samples t test for
normally distributed data or the Mann–Whitney U test for
non-normally distributed variables. MARD was compared
between treatments and participants by repeated-measures
analysis of variance to account for correlated data using
participant-level per-treatment MARD in the analysis. Dif-
ference in MARD between participants was tested by anal-
ysis of variance, and the null hypothesis was accepted if the
variance of random subject effect was not different from zero.
Results
CGM sensor data from 57 participants were analyzed: 41
adults (mean – SD age, 39 – 12 years; mean – SD hemoglo-
bin A1c, 7.9 – 0.8%) and 16 adolescents (mean – SD age,
15.6 – 3.6 years; mean – SD hemoglobin A1c, 8.1 – 0.8%).
Baseline demographics of participants are outlined in Table 1.
The average number of fingerstick capillary glucose mea-
surements performed by adult participants was 5.9 – 2.0 per
day, and that performed by adolescent participants was
4.3 – 2.4 per day.
Sensor numerical accuracy
The total duration of sensor use for the whole cohort was
2,002 days (48,052 h), equivalent to 90% of total study du-
ration (53,424 h). Duration of sensor use per week was higher
in the adult compared with the adolescent cohort (155.8
[148.7, 162.2] h vs. 149.7 [143.2, 152.4] h; P = 0.033). In
total, 10,647 sensor–capillary glucose pairs were available
for the analysis (Table 2). The overall numerical sensor ac-
curacy expressed as MARD and median ARD was 14.2 –
15.5% and 10.0% (4.5%, 18.4%), respectively. The MARD
in the euglycemia range was 13.9 – 13.3% (n = 6,223 pairs).
The Freestyle Navigator II CGM accuracy as measured by
ARD was higher in the hyperglycemic range (MARD,
9.8 – 8.8%; n = 3,410 pairs). In the hypoglycemic range (n =
1,014 pairs), MARD and median ARD were 30.6 – 28.7%
and 22.8% (11.2%, 41.2%), respectively. Information related
to sensor accuracy over the range of glucose values defined is
shown in the Bland–Altman plot in Figure 1. The distribution
of participant-level MARD over the whole capillary glucose
range and above 3.9 mmol/L shows that a greater propor-
tion of participants achieved MARD below 15% in the
euglycemia and hyperglycemia range (Supplementary Fig.
S1; Supplementary Data are available online at www
.liebertonline.com/dia). Overall, 70.0% of the Freestyle Nav-
igator II sensor readings were within ISO 15197:2013 15/15%
accuracy criteria (<3.9 mmol/L, 55.7%; 3.9–10.0 mmol/L,
67.5%; and >10.0 mmol/L, 78.7%).
MARD values per participant during CL and control pe-
riods were comparable for the whole cohort (13.9 – 15.0%
vs. 14.4 – 16.0%; P = 0.13). MARD was higher in adults
compared with adolescents (14.5 – 16.0% vs. 13.0 – 13.8%;
P < 0.001). Across the whole glucose range, MARD differ-
ences between participants was found to be statistically
significant (13.9%; 95% of the values fall within –4.1%;
P = 0.001); however, MARD between participants was more
comparable when excluding capillary glucose values at or
below 3.9 mmol/L from calculating MARD (12.3%; 95% of
the values fall within –3.7%; P = 0.06). The demographics
and clinical characteristics of participants (age, body mass
index, duration of diabetes, HbA1c, mean glucose level, SD
of glucose level, and percentage of time spent <3.9 mmol/L)
with the lowest sensor accuracy (MARD in the worst fourth
quartile) were compared against those with the highest ac-
curacy (MARD in the best first quartile) (Supplementary
Table S1). Proportion of time spent in the hypoglycemia
range was significantly higher in participants with the lowest
sensor accuracy (4.9% [2.8%, 8.5%] vs. 2.2% [1.5%, 5.2%];
P = 0.032). No other significant findings were observed.
Table 1. Baseline Demographics of Participants





Age (years) 39.5 – 11.6 15.4 – 2.0
Gender (male/female) 23/18 10/6
Body mass index (kg/m2) 26.1 – 3.4 21.7 – 2.2
Hemoglobin A1c (%) 7.9 – 0.8 8.1 – 0.9
Duration of diabetes (years) 24.8 – 11.6 7.2 – 4.3
Table 2. Sensor Accuracy for the Whole Glucose Range and Stratified According









Number of glucose sensor–capillary pairs 10,647 6,223 3,410 1,014
Mean capillary glucose (mmol/L) 8.6 – 3.9 6.9 – 1.7 13.3 – 2.8 3.2 – 0.5
Mean AD 1.0 – 1.0 0.9 – 0.8 1.3 – 1.2 0.9 – 0.8
Median AD 0.8 (0.4, 1.4) 0.7 (0.3, 1.2) 1.0 (0.4, 1.8) 0.7 (0.4, 1.2)
Mean ARD 14.2 – 15.5 13.9 – 13.3 9.8 – 8.8 30.6 – 28.7
Median ARD (%) 10.0 (4.5, 18.4) 10.4 (4.7, 18.6) 7.8 (3.4, 13.7) 22.8 (11.2, 41.2)
Bias 0.04 (1.44) 0.08 (1.3) - 0.25 (1.7) 0.7 (0.9)
ISO criteria (%)a 70.0 67.5 78.7 55.7
Data are mean – SD or median (interquartile range) values as indicated.
aInternational Organization for Standardization (ISO) 15197:2013 15/15% limits.
AD, absolute difference; ARD, absolute relative difference.
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Reciprocally, when first and fourth quartiles of participants’
demographics and clinical characteristics were compared,
sensor accuracy was significantly lower (MARD, 15.6%
[13.4%, 16.9%] vs. 12.2% [11.0%, 13.3%]; P = 0.01) in those
spending most time in the hypoglycemia range (Supple-
mentary Table S2).
Sensor clinical accuracy
The Freestyle Navigator CGM II had 96.3% of measure-
ments in CEG Zones A + B (Zone A, 80.1%; Zone B, 16.2%;
Zone C, 0.2%; Zone D, 3.5%; Zone E, 0.0%) (Fig. 2). During
the CL and control periods, 96.5% were in CEG Zones A + B
FIG. 1. Bland–Altman plot of sensor and capillary glucose levels. The solid black line represents the mean difference
between the sensor and capillary glucose values; the dashed lines indicate 1.96 · SD of the difference. CGM, continuous
glucose monitor.
FIG. 2. Clarke error grid of sensor and
capillary glucose levels. CGM, continuous
glucose monitor.
804 THABIT ET AL.
(Zone A, 80.3%; Zone B, 16.2%; Zone C, 0.2%; Zone D,
3.3%; Zone E, 0.0%), and 96.1% were in CEG Zones A + B
(Zone A, 79.9%; Zone B, 16.2%; Zone C, 0.3%; Zone D,
3.7%; Zone E, 0.0%), respectively.
Discussion
We investigated the numerical and clinical accuracy of the
Freestyle Navigator II CGM during three CL home studies
under free-living conditions. Our analysis suggests that in
ambulatory real-life conditions, the Freestyle Navigator II
CGM achieved nearly comparable MARD scores with those
reported in the manufacturer’s labeling and in controlled
research facility settings.9,17 The reliability and consistency
of CGM performance are particularly important in CL home
studies. As expected and shown in other studies, the Freestyle
Navigator II CGM was less accurate in the hypoglycemic
range compared with the euglycemic range when measured
by ARD (MARD, 30.6% vs. 13.9%), but absolute difference
was comparable (mean, 0.9 vs. 0.9 mmol/L). Nonetheless, the
accuracy measured by MARD was higher in the hypergly-
cemic range, and the Bland–Altman plot demonstrated rela-
tively few variations in sensor accuracy over the range of
measured glucose concentrations. Sensor accuracy was not
found to be significantly different between participants in the
euglycemic and hyperglycemic range, when insulin delivery
is actively modulated by the control algorithm. From a CL
perspective, this facilitates safer operation of CL by avoiding
hypoglycemia resulting from sensor over-reading, whereas
this risk is mitigated in the hypoglycemia range as insulin
delivery is suspended by the algorithm. The clinical rele-
vance of the accuracy analysis is further substantiated by the
percentage values in Zone A and B of the CEG analysis,
suggesting that over 95% of the input data to the control
algorithm from CGM had led to either clinically appropriate
decisions or avoided inappropriate treatment.
Previously published CGM accuracy studies were mostly
performed in clinical research facility settings.17,18 Experi-
mental conditions in inpatient studies do not fully reflect
free-living conditions, although such studies benefit from
gold-standard reference glucose measurements. Some studies
do not assess CGM performance across all glycemia ran-
ges.19,20 An inpatient head-to-head comparison study re-
ported superior overall accuracy for the Navigator CGM,
when compared with the Dexcom Seven Plus (Dexcom,
Inc., San Diego, CA; the latter superseded by Dexcom G4
Platinum) and the Guardian (Medtronic, Northridge, CA)
(now superseded by the Enlite sensor).8 When paired with
venous glucose measured by the GlucoScout (International
Biomedical, Austin, TX), the percentage points in Zone A of
the CEG were comparable to our analysis (80.6%). Another
recent inpatient study compared the Navigator, Dexcom
G4 Platinum, and Enlite CGM sensors.17 Using venous glu-
cose as reference, the Navigator and Dexcom G4 Platinum
had the best overall accuracy (MARD, 12.3% and 10.8%,
respectively).
Direct comparability to assess CGM performance during
home use of CL can be challenging, as inpatient studies
commonly use plasma or venous glucose as reference mea-
surements or for calibration. Such conditions are not practical
in routine clinical practice, and participants would normally
rely on capillary glucose measurements. Based on the limited
number of published reports on CGM performance in the
home environment, data from our analysis are comparable.
Kropff et al.7 compared the accuracy of the Dexcom G4
Platinum and Medtronic Enlite CGM system during 6 days of
home use. The overall accuracy in the home setting was
better for the Dexcom G4 Platinum compared with the Enlite
(MARD, 12.2 – 12.0% vs. 19.9 – 20.5%; P < 0.0001).
These findings were complemented by another ambulatory
head-to-head CGM home comparison study by Matulevi-
ciene et al.6 The accuracy of a modified Dexcom G4 Platinum
system with an enhanced calibration algorithm was recently
assessed over 7 days.21 The MARD during home use was
11.3%, with 92.4% in CEG Zone A. These studies were of a
shorter duration and had fewer numbers of CGM–capillary
glucose reference pairs available for analysis, especially in
the hypoglycemia range. To our knowledge, no other CL
home studies of similar duration have published data related
to CGM accuracy and performance.
The incidence and duration of large sensor errors are other
important determinants that may impact on the efficacy and
safety of a CL system. Although a continuous error grid
analysis has been specifically developed to evaluate CGM
performance,22 such a measurement tool has yet to be used
widely and does not provide information about the duration,
severity, and incidence of large sensor errors. A recent study
quantifying the incidence and duration of large inaccuracy
found that the Freestyle Navigator was safer for CL use
compared with the Dexcom Seven Plus.23 Although the
Dexcom Seven Plus has been superseded by Dexcom G4
Platinum with comparable performance to FreeStyle Navi-
gator in terms of large sensor errors,24 the report highlights
the unmet need of having additional measures to assess CGM
performance and reliability during CL operation.
Determining individual-level factors associated with re-
duced accuracy would help identify strategies to optimize
sensor performance. Post hoc analysis of our results revealed
that individuals with the most time spent in the hypoglycemia
range had lower MARD overall. This is consistent with
findings of lower MARD in the hypoglycemia range and may
potentially contribute to bias in studies reporting primarily on
hypoglycemia reduction outcomes. Further work is needed to
determine individual-level factors influencing sensor per-
formance and impact on CL performance.
The strengths of the present analysis are real-world settings
and the large dataset spanning a broad age range and geo-
graphical locations. We assessed sensor accuracy across a
wide glycemic range experienced by participants during free-
living conditions. Capillary glucose data used in the analysis
were obtained directly from the capillary blood glucose meter
built-in within the Freestyle Navigator CGM, thereby elim-
inating timing and transcription errors and standardizing
device use. The limitations include pre-analytical errors as-
sociated with fingerstick capillary glucose testing at home,
which may lead to erroneous measurements and calibration.
However, participants were instructed to perform hand
washing before performing fingerstick testing as per usual
clinical practice.
In summary, we observed high and consistent numerical
and clinical accuracy of the Freestyle Navigator II CGM in
the nonhypoglycemic range during home use in CL studies
during free-living conditions. In the hyperglycemic range, the
improved numerical accuracy facilitates safe operation of CL
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by avoiding hypoglycemia from CGM sensor over-reading.
Conversely, sensor inaccuracy at the hypoglycemic range is
mitigated by insulin delivery suspension during CL opera-
tion. Our analysis supports use of the Freestyle Navigator in
unsupervised CL home studies and may contribute toward
establishing CGM performance criteria for home use of
CL systems.
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